SCHEMBL1960198

SCHEMBL1960198

COC(=O)c1sccc1N(C(=O)c1ccc(Cl)cc1Cl)C1CCN(C)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CACNA2D1 P54289 5/20 0.45
▸ OPRM1 P35372 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.41
▸ RAB9A P51151 4/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ NPY1R P25929 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ F2 P00734 1/20 0.37
▸ F10 P00742 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961431 0.86 CACNA2D1 (0.41) CACNA2D1OPRM1ALDH1A1RAB9ACYP1A2
SCHEMBL1961686 0.81 NR1I2 (0.39) CACNA2D1OPRM1ALDH1A1RAB9ACYP1A2
SCHEMBL12578860 0.77 CACNA2D1 (0.39) CACNA2D1OPRM1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL1960227 0.77 RAB9A (0.42) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL4159892 0.75 MAPT (0.45) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2878267 0.74 ALDH1A1 (0.45) CACNA2D1OPRM1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2878269 0.74 ALDH1A1 (0.45) CACNA2D1OPRM1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2157663 0.74 OPRM1 (0.41) CACNA2D1OPRM1NPY1R
SCHEMBL2157606 0.74 MAPT (0.46) ALDH1A1RAB9ANPC1MAPTNPSR1
SCHEMBL4729162 0.73 CCR2 (0.36) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
EP-2504329-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2012-10-03 — — EP disclosed
WO-2011068715-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — WO disclosed
WO-2011068715-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS HAVCR2, GTF3C3, ZC3HAV1 CACNA2D1 4872/4885OPRM1 4338/4885ALDH1A1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback